SCHEMBL6035563

SCHEMBL6035563

CCOC(=O)CCc1cn(-c2ccc(C(F)(F)F)cn2)nc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
HPGD P15428 1/20 0.50
MAPT P10636 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
POLB P06746 3/20 0.43
GAA P10253 1/20 0.42
KDM4E B2RXH2 4/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
APAF1 O14727 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
GCGR P47871 1/20 0.38
FPR2 P25090 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036282 0.89 SMN1; SMN2 (0.47) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6034597 0.88 SMN1; SMN2 (0.47) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6034778 0.87 SMN1; SMN2 (0.46) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6036242 0.87 SMN1; SMN2 (0.46) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6034508 0.86 SMN1; SMN2 (0.45) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6035751 0.85 SMN1; SMN2 (0.45) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6036131 0.84 SMN1; SMN2 (0.46) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6035868 0.84 SMN1; SMN2 (0.43) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6035327 0.80 SMN1; SMN2 (0.61) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6034667 0.80 SMN1; SMN2 (0.40) SMN1; SMN2HPGDMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 SMN1; SMN2 4408/4885HPGD 3297/4885MAPT 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.